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Small doses of aspirin have been shown to inhibit platelet
thromboxane A2 while sparing vascular prostacyclin
synthesis. Because leukocytes generate prostacyclin and
participate in thrombosis along with platelets, the effects
of three different doses of aspirin (40, 325 and 650 mg)
on platelet function as wellas on endogenous biosynthesis
of thromboxane A2 and prostacyclin in whole blood were
examined. In normal volunteers given a single 40 mg
dose of aspirin, platelet aggregation and adenosine tri-
phosphate release were inhibited for 24 hours. In con-
trast, platelet function was inhibited for 4 to 7 days in
volunteers given 325 or 650 mg of aspirin. Platelet and
whole blood generation of thromboxane A2 was inhibited
Aspirin inhibits prostaglandin synthesis in human blood
platelets and blood vessels by acetylating enzyme cycloox-
ygenase (l,2). It has been proposed that 40 to 80 mg doses
of aspirin may inhibit platelet synthesis of thromboxane A2
while sparing or only minimally influencing vessel wall
synthesis of prostacyclin (3-5). This was shown recently
by Weksler et al. (5), who measured thromboxane A2 me-
tabolite in serum and prostacyclin metabolite in supernatants
of vascular tissues stimulated with arachidonate. Masotti et
al. (3) had earlier suggested that small doses of aspirin
differentially inhibited platelet aggregation and thrombox-
ane A2 production. These studies were, in part, a basis for
use of aspirin in a dose of 324 mg daily in patients with
unstable angina (6). Therapy with this dose of aspirin re-
sulted in greater than 50% reduction in mortality and mor-
bidity in this high risk group of patients.
Several recent studies (7-9) indicate that, in addition to
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less than 60% by the 40 mg dose, but almost completely
by both the 325 and 650 mg doses. Likewise, whole blood
generation of prostacyclin was inhibited 70% by the 40
mg dose and over 90% by the larger doses. Inhibition
of thromboxane A2 as well as of prostacyclin was evident
for 4 days with the 40 mg dose and for 7 days with the
larger doses. Decreases in whole blood thromboxane A2
and prostacyclin with any dose of aspirin were of similar
magnitude. These data indicate that aspirin in doses of
40 to 650 mg inhibits platelet function and biosynthesis
of thromboxane A2 and prostacyclin in whole blood in
human beings in a dose-dependent fashion.
platelets and blood vessels, leukocytes also synthesize
thromboxane A2 and prostacyclin. Measurement of throm-
boxane B2 • a stable metabolite ofthromboxane A2 , in serum
reflects thromboxane A2 production by platelets and leu-
kocytes in response to endogenously produced thrombin. In
contrast. serum concentrations of 6-keto-prostaglandin Flu
(POF t u) reflect prostacyclin synthesis by the leukocytes be-
cause platelets and erythrocytes do not synthesize prostacyclin.
To precisely define the effects of different doses of aspirin
in human beings, it is important to examine the production
of thromboxane A2 and prostacyclin by all blood compo-
nents. Accordingly. the purpose of this study was to evaluate
the effects of different doses of aspirin on whole blood
production of thromboxane A2 and prostacyclin. We related
the changes in prostanoid concentrations with effects on
platelet aggregation, nucleotide release and platelet throm-
boxane A2 generation.
Methods
Subjects. Fifteen normal healthy subjects (nine men and
six women. aged 22 to 37 years) volunteered for this study.
No subject had taken any drug in the preceding 10 days.
The subjects were randomly given aspirin. 40, 325 or 650
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Figure 1. Effect of aspirin on serum thromboxane H2• A 40 mg
dose of aspirin significantly (p < 0 .02) inhibited whole blood
thromboxane H2 generation for 4 days. In contrast, both the 325
and 650 mg doses inhibited thromboxane H2 for 7 days. Data are
expressed as mean ± standard error. C = control before aspirin .
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Results
Serum thromboxane B2 and 6-keto-PGFI,. concentra-
tions. Before aspirin administration, serum thromboxane
Bz levels ranged from 172 to 650 ng/ml (mean 383 ± 32).
There were no differences in control serum thromboxane
Bz levels in groups of subjects taking different doses of
aspirin . One hour after administration of aspirin in doses of
40 . 325 and 650 mg, thromboxane B2 levels decreased by
51 ± 5, 98 ± 1 and 99 ± I%, respectively (percent
decrease: 325 versus 650 mg dose, p == NS; 40 versus 325
or 650 mg dose, p < 0.01) . Significant (p < 0.05) inhibition
of thromboxane B2 occurred for at least 7 days with either
the 325 or the 650 mg dose, but only for 4 days in subjects
given the 40 mg dose (Fig . I) . Recovery of thromboxane
B2 began 2 days after aspirin administration in all instances.
In all serum samples, 6-keto-PGF1a (mean 3.27 ± 0.25)
was identified and ranged from 2.25 to 7.00 ng/ml before
aspirin administration; the levels were similar in all groups
of subjects and decreased significantly I hour after aspirin .
Aspirin, 40 mg, caused a smaller (p < 0.01) decrease (mean
59 ± 3%) than either the 325 or 650 mg dose (mean de-
creases: 99 ± I and 99 ± 0.5%, respectively) . During the
II day period, prostacyclin production gradually recovered,
as evident by an increase in 6-keto-PGFl a levels in serum;
the levels on day 4 in subjects given 40 mg of aspirin were
still lower (p < 0.02) than control values, but similar to
control values on days 7 and II . In subjects given 325 or
650 mg of aspirin , serum levels of 6-keto-PGF la were sig-
mg orally , as a single dose . All aspects of these studies
were approved by the Institutional Review Board . The study
design was explained to each participant before obtaining
informed written consent.
Blood collection. Peripheral venous blood was collected
before and 1,24,48,96 and 168 hours after aspirin admin-
istration . In 12 subjects , blood was also collected on the
II th day after aspirin administration. Blood (9 ml) was
collected in polypropylene tubes in I ml of 3.8% sodium
citrate for determination of platelet aggregation and aden-
osine triphosphate (ATP) and thromboxane Az release . An-
other 2 ml of blood was collected in glass tubes for deter-
mination of serum thromboxane Bz and 6-keto-PGF t a levels.
Platelet studies. Citrated blood was centrifuged to ob-
tain platelet-rich and platelet-poor plasma fractions. Platelet
count was adjusted at approximately 300,000 counts/mrrr',
and maximal platelet aggregation in response to adenosine
diphosphate (ADP) or epinephrine was determined as de-
scribed previously (10, II). The amount of ADP or epi-
nephrine used each time in the same individual was the
minimal concentration that caused complete and irreversible
aggregation before aspirin administration. Concomitant with
platelet aggregation, platelet ATP release was quantitated
by comparison with deflection caused by a known amount
of A I'P using Chronolume, a firefly extract (Chronolog Cor-
poration). The technique has been described in detail else-
where (10 ,12). After quantitation of platelet aggregation.
platelet-rich plasma samples stimulated with ADP were stored
in solution containing aspirin (1 mM) and ethylenediami-
netetraacetic acid (4.5 roM) to prevent additional in vitro
thrornboxane Az generation (13) . The samples were stored
at - 70°C for determination of thromboxane Bz.
Serum thromboxane B2 and 6-keto-PGFI,. concentra-
tions and measurements. Whole blood was allowed to clot
at 37°C for I hour in a water bath to pennit maximal gen-
eration of thromboxane Az and prostacyclin (8). The serum
was then separated by centrifugation at 1.000 g for 5 minutes
and stored at - 70°C for measurement of thromboxane B2
and 6-keto-PGF1,. .
These stable hydroly sis products of thromboxane Az and
prostacyclin , respectively , were measured as described pre-
viously (13 ,14) . All measurements were made by radioim-
munoassay using commercially available kits (New England
Nuclear Corporation) and completed within I month after
the collection of blood. Thromboxane Bz was expressed in
ng/ml of serum or ng/108 platelets in ADP-stimulated plate-
let-r ich plasma; 6-keto-PGF1a was expressed in ng/ml of
serum .
Calculations. All measurements were made in dupli-
cate , and the averages were used for calculation of mean
and standard error. Student's t test , analysis of variance and
correlation coefficients where appropriate were used for sta-
tistical calculations. A probability value of less than 0.05
was considered significant.
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Figure 2. Effect of aspirin on serum 6-keto-PGF ,U' A small dose
of aspirin. 40 mg. significantl y (p < 0.02) inhibited whole blood
prostacyclin gene ration for 4 days. In contra st. both the 325 and
650 mg doses inhibited prostacyclin biosynthesis for 7 days. Ab-
breviations as in Figure I.
gradual return of the secondary wave by day II . The mag-
nitudes of inhibition of platelet aggregation by the 325 and
650 mg doses were similar.
Platelet ATP release. After 40 mg of aspirin, platelet
ATP release in response to ADP and epinephrine was sig-
nificantly (p < 0.02) reduced for only 24 hours and returned
to control values by 48 hours (Fig. 3 and 4). Higher doses
of aspirin inhibited ADP-induced ATP release for at least
7 days. Values for ATP release were similar to control
values on day II (Fig. 3). Epinephrine-induced platelet ATP
release was also inhibited for 4 days after 325 mg. and for
7 days after 650 mg of aspirin (Fig. 4).
Platelet thromboxane A2 generation. Thromboxane A2
generated by platelets was decreased for 4 days after 40 mg
of aspirin, and for 7 days after the 325 or 650 mg dose of
aspirin (Table 2). There were no differences in thromboxane
A2 production of platelets in response to the 325 or 650 mg
dose. but magnitude of inhibition was less with the 40 mg
dose compared with higher doses (p < 0.01). A decrease
in platelet thromboxane A2 generation correlated with a
decrease in whole blood thromboxane A2 generation (r
0.95).
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nificantly lower (p < 0.02) on day 7. but similar to control
values on day 11 (Fig. 2).
Comparison of serum thromboxane 8 2 and 6-keto-PGF'a
data showed that each dose of aspirin inhibited both throm-
boxane Az and prostacyclin by a similar magnitude. In ad-
dition, 40 mg of aspirin caused less inhibition than either
the 325 or the 650 mg dose and for a shorter time (4 versus
7 days; p < 0.02).
Platelet aggregation. Data relative to platelet aggre-
gation in response in threshold concentrations of ADP and
epinephrine are shown in Table I. Aspirin, 40 mg. caused
a modest decrease in both ADP- and epinephrine-induced
platelet aggregation 1 hour after aspirin administration. The
decrease, however, was not observed thereafter. In contrast,
both the 325 and 650 mg doses of aspirin inhibited the
secondary wave of platelet aggregation for 4 days with a
Discussion
Aspirin and thrombosis. It has been suggested that small
doses of aspirin may be useful in thrombotic disorders by
inhibiting platelet aggregation and thromboxane A2 synthe-
sis while sparing vascular synthesis of prostacyclin ( 15) . In
contrast. higher doses of aspirin not only may lose this
preferential effect on platelet activity, but may even promote
platelet deposition on injured vessels ( 16, 17) and enhance
atherogenesis (18). If the hypothesis of thromboxane A2-
prostacyclin "balance" in regulation of vascular tone and
platelet homeostasis is accepted, selective inhibition of
thromboxane A2 and platelet activation would appear to be
a logical therapeutic approach.
Aspirin, thromboxane A2 and prostacyclin. Dif-
ferential effects of small doses of aspirin on thromboxane
A2 and prostacyclin synthesis by platelets and blood vessels.
Table 1. Influence of Aspirin on Platelet Aggregation in 15 Normal Subjects
Dose of Aggregation
Platelet Aggregation Before and After Aspmn ( 'It)
Aspirin (rng) Snrnulus Control I Hour I Day 2 Days 4 Days 7 Days II Days
40 ADP 57 ~ 5 46 ~ 9' 59 :!: 4 66 ± 8 65 := 4 74 ± 4 68 :!' 3
Epinephrine 67 ± 2 47 ± I' 66 ± 1 69 ± 4 61 ± 6 74 ± 3 68 ± 5
325 ADP 54 := 6 42 := 4' 42 :!: 9' 35 ± 2' 36 ± 8' 58 ± 8 67 ± 4
Epinephrine 59 ± 8 23 ± 4' 31 :!: 2* 32 :!: I' 48 ± 6' 62 ± 4 62 ::t 2
650 ADP 60 ± 2 34 ± 3' 40 ± 3' 45 ± 3' 41 ± 4' 47 ± 6 65 ± 4
Epinephrine 66 ± 4 29 ± 3' 32 :!: 2' 37 ± 2' 33 ± 3' 61 ± :1 62 ± 5
' p < 0.01 (aspirin versus control). Values are expressed as mean ± standard error.
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Figure 3. Aspirin and ADP-induced platelet ATP release, ATP
release was significantly (p < 0,02) inhibited for only 24 hours
after .f0 mg of aspirin. but for 7 days after either 325 or 650 mg
of aspirin. Abbreviations as in Figure I.
Figure 4. Aspirin and epinephrine-induced platelet ATP release.
ATP release was inhibited for 24 hours after 40 mg of aspirin, for
4 days after 325 mg of aspirin and for 7 days after 650 mg of
aspirin. Abbreviations as in Figure I.
respectively , have been demonstrated. Massotti (3), Hanley
(4) and Weksler and their coworkers (5) showed preferential
and selective inhibition of platelet thromboxane A2 gener-
ation by 40 to 80 mg doses of aspirin, while prostacyclin
synthesis in blood vessels was less affected . Preston et al.
(19 .~0). however, using a similar approach , could not iden-
tify these selective effects of 40 to 80 mg doses of aspirin
in human tissues. Patrignani et al. (7) showed that 0.45
mg.kg per day of aspirin significantly reduced serum throrn-
boxane B2 • Urinary 6-keto-PGF1o was reduced by only 20%.
but this decrease was not statistically significant. FitzGerald
et al (21) measured urinary metabol ites of prostacycIin and
thromboxane A2 under the influence of aspirin . 20 mg to
2.6 g daily . These investigators described a dose-dependent
decrease in excretion of these prostanoid s. although the
decrease in prostacycIin was less than that in thromboxane
A2. As recognized by the investigators, the concentrations
of metabolites in urine reflect release of prostacyclin and
thromboxane A2 from all sources including kidneys, lungs,
leukocyte s, platelets and blood vessels.
Serum thromboxane B2 concentrations reflect thrombox-
ane A2 production by platelets and leukocytes (5,7,8), whereas
6-keto-PGF l o concentrations indicate production of pros-
tacyclin mainly by leukocytes on stimulation with endog-
enous thrombin (9,22) . It is clear from our data that all three
doses of aspirin (40, 325 and 650 mg) inhibited thromboxane
A 1 format ion in platelet suspensions and serum, confirming
previous reports (5, 7. 21). Magnitude and duration of in-
hibition of thromboxane A2 were dose-dependent as ob-
served by FitzGerald et al. (21) . A 40 to 60% inhibition of
serum thromboxane 8 2 by a single 40 mg dose of aspirin
lasted for 4 days . In contra st, larger doses caused much
Table 2. Aspirin and Platelet Thromboxane A2 Generation
Thrornboxane B, lng/ lOX platelets)
Dose of 1 Day 4 Day ~ 7 Days 11 Days
Aspirin (mg) Before Aspmn After Aspirin After Aspirin After Aspinn After Aspirin
40 5.3 ~ 0.5 23 :t0 " 2 3 :! 0" 5.9 :!: 0.7 5.1 ~ 0.4
l25 5.0 :! 06 0.3 ± 0 I' 1.3 ± 0.2* 3.7:! D3t 6.5 :! 0.9
1)50 5.2 :!: 0 4 D.3 :t 0 I' I 2 :! 0.1* 3.8 :!: 0.3* 5.9 :! 0.4
'p < 0.01; t p < 0.02 compared with values before aspmn
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more inhibition that lasted for 7 days. Recovery of throm-
boxane A2 began 2 days after aspirin administration in all
subjects.
The effects of aspirin on prostacyclin generation in whole
blood were similar to its effects on thromboxane A2 syn-
thesis. Concentrations of 6-keto-PGF l a in serum were in-
hibited 40 to 70% by a 40 mg dose of aspirin. This inhibition
was evident I hour after aspirin and lasted up to 4 days.
Higher doses of aspirin caused a total inhibition of pros-
tacyclin for 2 days with subsequent recovery. Thus, similar
to thromboxane A2 inhibition, prostacyclin release in whole
blood was inhibited by aspirin in a dose-dependent fashion.
These data on the effects of aspirin are different from pre-
vious observations (3,4,5,7,21) with regard to inhibition of
prostacyclin biosynthesis. However, we measured prosta-
cyclin biosynthesis in whole blood as opposed to that in
blood vessels or excretion of prostacyclin metabolites in the
urine.
Effects of aspirin on platelet aggregation and ATP
release. Platelet aggregation and ATP release in response
to ADP and epinephrine were also dependent on the dose
of aspirin administered. The smallest dose of aspirin (40
mg) inhibited platelet aggregation for less than 24 hours,
whereas higher doses (325 and 650 mg) had inhibitory ef-
fects lasting at least 4 days. It is noteworthy that the inhi-
bition of platelet aggregation was less marked than that of
thromboxane A2 . In addition, platelet aggregation returned
to control values sooner than did thromboxane A2 . Platelets
are capable of aggregating in vitro while thromboxane A2
synthesis is inhibited (23,24). Recovery of platelet aggre-
gation function reflects the aggregation potential of small
amounts of uninhibited thromboxane A2 (23). Inhibition of
ATP release from the platelets was as marked as that of
thromboxane A2 release. These data indicate that platelet
aggregation alone may not be affected, while intracellular
release processes are inhibited by aspirin.
Vessel wall versus leukocyte synthesis of prostacy-
clin, Vascular tissues are important sources of prostacyclin,
but leukocytes also are capable of producing substantial
amounts. The capability of blood vessels to generate pros-
tacyclin is generally believed to be suppressed in tissues
obtained from patients or animals with atherosclerosis
(14,25,26). In patients with atherosclerosis, therefore, pro-
duction of prostacyclin by leukocytes may be important.
Furthermore, leukocytes are incorporated in the intraarterial
platelet thrombus. Activated leukocytes may exert a regu-
latory role in thrombogenesis by producing prostacyclin.
However, isolated leukocytes have limited capability to me-
tabolize arachidonic acid and may depend on availability of
cyclic endoperoxides to synthesize prostacyclin. It is pos-
sible that in whole blood, leukocytes utilize platelet-gen-
erated cyclic endoperoxides to synthesize prostacyclin. Sim-
ilar degrees of inhibition of prostacyclin and thromboxane
A2 in whole blood by aspirin observed in our study are
consistent with this hypothesis.
Clinical implications. Trials of aspirin in doses ranging
from 325 to 1,500 mg per day have provided the suggestion
of benefit in patients with previous myocardial infarction
(27-29), but the data did not reach statistical significance
in any single study. The lack of statistically significant re-
sults has been thought to be due to inhibition of prostacyclin
by the large doses of aspirin employed. However, a recent
Veterans Administration cooperative trial (6) demonstrated
a significant reduction in cardiovascular morbidity and mor-
tality in patients with unstable angina given 324 mg of
aspirin daily. This dose would be expected to reduce both
vessel wall and leukocyte prostacyclin synthesis (7,2 \).
Therefore, the improvement with aspirin cannot be ascribed
to "selective" inhibition of thromboxane A2 • It is quite
possible that the importance of prostacyclin has been "ov-
eremphasized" as noted in two recent editorials (30,31) and
that thromboxane A2 inhibition is beneficial. It should be
recognized that in addition to thromboxane A2 inhibition,
other effects of aspirin, such as reduction in arrhythmias,
infarct size, catecholamine-induced vasoconstriction and li-
polysis (32-34), may also contribute to the benefit seen in
these patients.
In summary, our study has shown that aspirin inhibits
whole blood thromboxane A2 and prostacyclin synthesis and
platelet function in a dose-dependent manner. We could not
identify any dose that would selectively inhibit thromboxane
A2 in whole blood. Differences between the present study
and some previous studies relate to the role of leukocytes
in generating prostacyclin, which was not examined by other
investigators.
We thank Kelly Greetham for a,sistance in the preparation of th" manu'Cnpt.
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